Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS).

Trial Profile

Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Alefacept (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms ATLAS
  • Most Recent Events

    • 07 Mar 2012 Actual patient number (1897) added as reported by ClinicalTrials.gov
    • 07 Mar 2012 Planned end date changed from 1 Dec 2025 to 1 Jan 2012 as reported by ClinicalTrials.gov
    • 07 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top